Date | Title | Description | _References |
09.01.2023 | ATP and NY... | ;Aethon’s HapImmune™ platform,... | Array;Arra... |
09.01.2023 | ATP and NY... | Aethon’s HapImmune™ platform, ... | Array;Arra... |
06.01.2023 | Intergalac... | BOSTON, Jan. 6, 2023 /PRNewswi... | Array;Arra... |
06.01.2023 | Intergalac... | BOSTON, Jan. 6, 2023 /PRNewswi... | Array;Arra... |
04.01.2023 | Ascidian T... | BOSTON, Jan. 4, 2023 /PRNewswi... | Array;Arra... |
04.01.2023 | Ascidian T... | BOSTON, Jan. 4, 2023 /PRNewswi... | Array;Arra... |
08.12.2022 | FDA Accept... | Prescription Drug User Fee Act... | Array;Arra... |
08.12.2022 | FDA Accept... | Prescription Drug User Fee Act... | Array;Arra... |
02.12.2022 | Stoke Ther... | Single and multiple doses of S... | Array;Arra... |
02.12.2022 | Stoke Ther... | Single and multiple doses of S... | Array;Arra... |
29.11.2022 | Stoke Ther... | Seven abstracts related to the... | Array;Arra... |
29.11.2022 | Stoke Ther... | Seven abstracts related to the... | Array;Arra... |
14.11.2022 | Stoke Ther... | Company announces positive int... | Array;Arra... |
14.11.2022 | Stoke Ther... | Company announces positive int... | Array;Arra... |
10.11.2022 | Aulos Bios... | - | - |
10.11.2022 | Marengo Th... | - | - |
10.11.2022 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... | Array;Arra... |
10.11.2022 | Galvanize ... | INCITE ES clinical study resul... | Array |
10.11.2022 | Marengo Th... | STAR0602 expands both pre-exis... | - |
10.11.2022 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... | Array;Arra... |
10.11.2022 | Galvanize ... | INCITE ES clinical study resul... | Array |
10.11.2022 | Aulos Bios... | Data show trend in decreasing ... | Array;Arra... |
31.10.2022 | Aulos Bios... | AU-007 represents the company’... | Array;Arra... |
31.10.2022 | Aulos Bios... | - | - |
28.10.2022 | Marengo Th... | - | - |
28.10.2022 | Marengo Th... | Compelling data with STAR0602 ... | Array |
17.10.2022 | New Biotec... | NEW YORK, Oct. 17, 2022 /PRNew... | Array;Arra... |
17.10.2022 | New Biotec... | NEW YORK, Oct. 17, 2022 /PRNew... | Array;Arra... |
12.10.2022 | Marengo Th... | STAR0602 demonstrates potent, ... | Array |
12.10.2022 | Ascidian T... | ATP incubated and built Ascidi... | Array;Arra... |
12.10.2022 | Ascidian T... | ATP incubated and built Ascidi... | Array;Arra... |
12.10.2022 | Marengo Th... | STAR0602 demonstrates potent, ... | Array |
11.10.2022 | Aulos Bios... | LARKSPUR, Calif.--(BUSINESS WI... | Array;Arra... |
11.10.2022 | Aulos Bios... | - | - |
22.09.2022 | Nereid The... | Clifford Brangwynne, Ph.D., co... | Array |
22.09.2022 | Nereid The... | Clifford Brangwynne, Ph.D., co... | Array |
20.09.2022 | How 3 comp... | By Ron Leuty
Republished with... | - |
20.09.2022 | How 3 comp... | By Ron Leuty;Republished with ... | - |
16.09.2022 | Marengo Th... | CAMBRIDGE, Mass., Sept. 16, 20... | Array |
16.09.2022 | Marengo Th... | CAMBRIDGE, Mass., Sept. 16, 20... | Array |
15.09.2022 | Galvanize ... | Merger unites three companies ... | Array |
15.09.2022 | Galvanize ... | Merger unites three companies ... | Array |
14.09.2022 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., S... | - |
14.09.2022 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., S... | - |
13.09.2022 | Nine Squar... | SOUTH SAN FRANCISCO, Calif., S... | Array;Arra... |
13.09.2022 | Nine Squar... | SOUTH SAN FRANCISCO, Calif., S... | Array;Arra... |
13.09.2022 | In Akero T... | 50mg (41%) and 28mg (39%) grou... | Array;Arra... |
13.09.2022 | In Akero T... | 50mg (41%) and 28mg (39%) grou... | Array;Arra... |
25.08.2022 | Stoke Ther... | ADOA is primarily caused by mu... | Array;Arra... |
25.08.2022 | Stoke Ther... | ADOA is primarily caused by mu... | Array;Arra... |
24.08.2022 | Study Publ... | 33% improved by one fibrosis s... | Array;Arra... |
24.08.2022 | Study Publ... | 33% improved by one fibrosis s... | Array;Arra... |
08.08.2022 | Stoke Ther... | In the fourth quarter, the Com... | Array;Arra... |
08.08.2022 | Stoke Ther... | In the fourth quarter, the Com... | Array;Arra... |
01.08.2022 | Ipsen and ... | Multi-year collaboration will ... | Array;Arra... |
01.08.2022 | Ipsen and ... | Multi-year collaboration will ... | Array;Arra... |
26.07.2022 | Precision ... | Companies aim to support devel... | Array |
26.07.2022 | Precision ... | Companies aim to support devel... | Array |
12.07.2022 | Replicate ... | SAN DIEGO, Calif., July 12, 20... | - |
12.07.2022 | Marengo Th... | E. John Wherry, Ph.D., and Jam... | Array |
12.07.2022 | Replicate ... | SAN DIEGO, Calif., July 12, 20... | - |
12.07.2022 | Marengo Th... | E. John Wherry, Ph.D., and Jam... | Array |
16.06.2022 | Akero Ther... | $25 Million Equity Investment ... | - |
16.06.2022 | Akero Ther... | $25 Million Equity Investment ... | - |
15.06.2022 | Marengo Th... | - | - |
15.06.2022 | Marengo Th... | CAMBRIDGE, Mass., June 15, 202... | Array |
09.06.2022 | Curia and ... | - | - |
09.06.2022 | Curia and ... | ALBANY, N.Y.--(BUSINESS WIRE)-... | Array;Arra... |
01.06.2022 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... | Array;Arra... |
01.06.2022 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... | Array;Arra... |
26.05.2022 | Aulos Bios... | - | - |
26.05.2022 | Aulos Bios... | Trials in Progress poster desc... | Array;Arra... |
10.05.2022 | Stoke Ther... | 2H 2022 clinical data readout ... | Array;Arra... |
10.05.2022 | Stoke Ther... | 2H 2022 clinical data readout ... | Array;Arra... |
09.05.2022 | Marengo Th... | Further demonstrates confidenc... | Array |
09.05.2022 | Marengo Th... | - | - |
05.05.2022 | Aulos Bios... | - | - |
05.05.2022 | Aulos Bios... | Clinical program advancement r... | Array;Arra... |
02.05.2022 | Stoke Ther... | Data presented at the Associat... | Array;Arra... |
02.05.2022 | Stoke Ther... | - | - |
27.04.2022 | Aulos Bios... | - | - |
27.04.2022 | Aulos Bios... | LARKSPUR, Calif.--(BUSINESS WI... | Array;Arra... |
07.04.2022 | Stoke Ther... | New preclinical data support t... | Array;Arra... |
07.04.2022 | Stoke Ther... | New preclinical data support t... | Array;Arra... |
05.04.2022 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... | Array;Arra... |
05.04.2022 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... | Array;Arra... |
21.03.2022 | Aulos Bios... | Data show significant tumor gr... | Array;Arra... |
21.03.2022 | Aulos Bios... | Data show significant tumor gr... | Array;Arra... |
10.03.2022 | Stoke Ther... | – Enrollment and dosing ongoin... | Array;Arra... |
10.03.2022 | Stoke Ther... | – Enrollment and dosing ongoin... | Array;Arra... |
09.03.2022 | Marengo Th... | CAMBRIDGE, Mass., March 9, 202... | Array |
09.03.2022 | Marengo Th... | CAMBRIDGE, Mass., March 9, 202... | Array |
07.03.2022 | Apple Tree... | All of us at Apple Tree Partne... | Array |
07.03.2022 | Apple Tree... | All of us at Apple Tree Partne... | Array |
03.03.2022 | ATP Statem... | Apple Tree Partners (ATP) stan... | - |
03.03.2022 | ATP Statem... | Apple Tree Partners (ATP) stan... | - |
23.02.2022 | Aulos Bios... | New data demonstrate eradicati... | Array;Arra... |
23.02.2022 | Aulos Bios... | New data demonstrate eradicati... | Array;Arra... |
08.02.2022 | Gala Thera... | SAN CARLOS, Calif., Feb. 8, 20... | - |
08.02.2022 | Gala Thera... | SAN CARLOS, Calif., Feb. 8, 20... | - |
20.01.2022 | Intergalac... | BOSTON, Mass., January 20, 202... | Array;Arra... |